SARS-CoV-2 Infection of Airway Epithelium Triggers Pulmonary Endothelial Cell Activation and Senescence Associated with Type I IFN Production.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
17 09 2022
Historique:
received: 21 07 2022
revised: 09 09 2022
accepted: 14 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Airway epithelial cells represent the main target of SARS-CoV-2 replication but several pieces of evidence suggest that endothelial cells (ECs), lining pulmonary blood vessels, are key players in lung injury in COVID-19 patients. Although in vivo evidence of SARS-CoV-2 affecting the vascular endothelium exists, in vitro data are limited. In the present study, we set up an organotypic model to dissect the crosstalk between airway epithelium and pulmonary endothelial cells during SARS-CoV-2 infection. We showed that SARS-CoV-2 infected airway epithelium triggers the induction of endothelial adhesion molecules in ECs, suggesting a bystander effect of dangerous soluble signals from the infected epithelium. The endothelial activation was correlated with inflammatory cytokines (IL-1β, IL-6, IL-8) and with the viral replication in the airway epithelium. Interestingly, SARS-CoV-2 infection determined a modulation of endothelial p21, which could be partially reversed by inhibiting IFN-β production from ECs when co-cultured with HAE. Altogether, we demonstrated that SARS-CoV-2 infected epithelium triggers activation/senescence processes in ECs involving type I IFN-β production, suggesting possible antiviral/damage mechanisms occurring in the endothelium.

Identifiants

pubmed: 36139488
pii: cells11182912
doi: 10.3390/cells11182912
pmc: PMC9496907
pii:
doi:

Substances chimiques

Interferon Type I 0
Interleukin-6 0
Interleukin-8 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Cells. 2022 May 29;11(11):
pubmed: 35681476
mBio. 2020 Dec 11;11(6):
pubmed: 33310781
Cell Rep. 2015 May 5;11(5):785-797
pubmed: 25921537
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Signal Transduct Target Ther. 2020 Dec 24;5(1):293
pubmed: 33361764
EMBO Rep. 2021 Jun 4;22(6):e52744
pubmed: 33908688
Am J Respir Crit Care Med. 2019 Sep 1;200(5):556-564
pubmed: 30860857
Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1760-1773
pubmed: 33626910
Mitochondrion. 2020 Sep;54:1-7
pubmed: 32574708
Br J Dermatol. 2020 Oct;183(4):729-737
pubmed: 32562567
Cell Death Dis. 2020 Dec 8;11(12):1042
pubmed: 33293527
Nature. 2022 Mar;603(7899):145-151
pubmed: 35045565
Nature. 2017 Oct 19;550(7676):402-406
pubmed: 28976970
J Mol Cell Cardiol. 2022 Mar;164:69-82
pubmed: 34838588
Cell. 2017 Jun 1;169(6):1000-1011
pubmed: 28575665
Signal Transduct Target Ther. 2021 Jul 12;6(1):266
pubmed: 34253708
Sci Rep. 2017 Jan 03;7:39501
pubmed: 28045034
Nature. 2021 Nov;599(7884):283-289
pubmed: 34517409
iScience. 2022 Feb 18;25(2):103854
pubmed: 35128349
Genes Dev. 2013 Nov 1;27(21):2356-66
pubmed: 24186980
Sci Rep. 2016 Nov 16;6:37007
pubmed: 27849057
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Eur Respir J. 2020 Dec 24;56(6):
pubmed: 33033152
Lung. 2006 Sep-Oct;184(5):259-66
pubmed: 17235725
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Cell Physiol Biochem. 2017;43(4):1369-1380
pubmed: 28992616
Virulence. 2016 May 18;7(4):427-42
pubmed: 26809688
Front Cell Infect Microbiol. 2021 Jul 06;11:701278
pubmed: 34307198
Nat Rev Immunol. 2007 Oct;7(10):803-15
pubmed: 17893694
Circ Res. 2021 Apr 30;128(9):1323-1326
pubmed: 33784827
Sci Transl Med. 2021 Nov 17;13(620):eabj7790
pubmed: 34648357
Lab Invest. 2005 Apr;85(4):502-11
pubmed: 15711569
Nat Rev Immunol. 2020 Jul;20(7):389-391
pubmed: 32439870
Am J Physiol. 1992 Feb;262(2 Pt 1):C461-9
pubmed: 1539634
JCI Insight. 2021 Sep 8;6(17):
pubmed: 34314391
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Clin Exp Med. 2022 Jan 21;:
pubmed: 35061142
Arthritis Rheum. 2007 Nov;56(11):3759-69
pubmed: 17968925
J Virol. 2002 Dec;76(23):12135-48
pubmed: 12414954

Auteurs

Veronica Bordoni (V)

Cellular Immunology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Davide Mariotti (D)

Cellular Immunology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Giulia Matusali (G)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Francesca Colavita (F)

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Eleonora Cimini (E)

Cellular Immunology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Giuseppe Ippolito (G)

General Directorate for Research and Health Innovation, Italian Ministry of Health, 00144 Rome, Italy.

Chiara Agrati (C)

Cellular Immunology Laboratory, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH